Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YDBZU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SHR-4602
|
|||||
| Synonyms |
SHR 4602; SHR-4602; SHR4602
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Pertuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Eribulin derivatives ER300
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
